- Company name
- Insmed
- Sector
- Biotechnology: respiratory and rare diseases
- About
- Insmed Incorporated (INSM) is a US biopharmaceutical company. It sells two drugs. BRINSUPRI (brensocatib) treats non-cystic fibrosis bronchiectasis, a chronic lung disease. The FDA approved it on August 12, 2025, the European Commission in November 2025, the United Kingdom in February 2026 and Japan in August 2026. ARIKAYCE treats Mycobacterium avium complex (MAC) lung disease. The main drug in development is TPIP (treprostinil palmitil inhalation powder), which is in Phase 3 studies for pulmonary hypertension and lung fibrosis. Revenue was $524.4 million in the third quarter of 2026, of which $400.1 million came from BRINSUPRI and $124.4 million from ARIKAYCE. The head office is in Bridgewater, New Jersey, and Will Lewis is chair and chief executive officer.
- Thesis
- The market prices Insmed close to the AI estimate because most of its value depends on how far BRINSUPRI sales can grow, and on TPIP, which is still in Phase 3. BRINSUPRI revenue grew from $207.9 million in the first quarter of 2026 to $400.1 million in the third quarter, and Insmed raised its 2026 guidance twice. But Insmed still had a net loss of $100.3 million in the third quarter, because research and selling costs grow fast. For the value to rise, three things must be true. BRINSUPRI sales must keep growing toward the peak of more than $7 billion that Insmed expects, with launches in Europe and Japan. Insmed must become cash flow positive in 2027, as it expects. And the FDA must approve the ARIKAYCE label expansion by the target date of January 28, 2027. The fourth quarter 2026 report, expected in early 2027, is the next test of BRINSUPRI demand. The TPIP Phase 3 results come later: Insmed expects to complete enrollment of PALM-ILD in the first half of 2028.
- Valuation
- The intrinsic value for Insmed is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Insmed with the SEC. Insmed is not yet profitable, so the method is a multiple of net income per share in 2030, discounted to today at 10% a year for four years, plus net cash per share. The third quarter 2026 release (8-K, October 29, 2026) gives revenue of $524.4 million for the quarter, of which BRINSUPRI was $400.1 million and ARIKAYCE $124.4 million, and a net loss of $100.3 million. It raises the 2026 revenue guidance to $1.35 billion to $1.4 billion for BRINSUPRI and $460 million to $470 million for ARIKAYCE. It says that Insmed expects peak revenue of more than $7 billion for BRINSUPRI, more than $6 billion for TPIP and more than $1 billion for ARIKAYCE. The Form 10-Q for the quarter gives cash, cash equivalents and marketable securities of $1,146.6 million, term loans of $546.8 million including capitalized interest, a royalty financing liability of $156.5 million and contingent consideration of $178.1 million at September 30, 2026, so the estimate uses net cash of $265.2 million. It gives 219,380,309 shares outstanding on October 23, 2026, and 14,406,000 options, 3,343,000 RSUs and 183,000 PSUs at September 30, 2026. The estimate counts all of them as shares and adds no exercise cash, so it uses 237,312,309 shares. The 2030 revenue, the operating margin after royalties, the tax rate of 20%, the multiples and the discount rate are assumptions. The low case assumes 2030 revenue of $3.6 billion, because BRINSUPRI grows slowly after the first years of launch, an operating margin of 30% and 18 times. It gives $45.88 per share. The base case assumes $5.8 billion, with $5.0 billion from BRINSUPRI and $0.8 billion from ARIKAYCE, a margin of 40% and 22 times. It gives $118.64 per share. The high case assumes $7.9 billion, with $6.5 billion from BRINSUPRI and a first $0.5 billion from TPIP, a margin of 45% and 25 times. It gives $205.75 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $122.23 per share. Intangible assets apply. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis in the United States, the European Union, the United Kingdom and Japan, where Insmed calls it the first and only approved treatment for the disease, and patents and regulatory exclusivity protect it and ARIKAYCE. But most of the value depends on one new drug, and other companies can develop drugs for the same disease, so the estimate expects an advantage that lasts 10 years or more, but not 20 years.
As of Nov 14, 2026.
- Risks
- Most of the expected growth comes from one drug, BRINSUPRI. If the launch slows, for example because of slow diagnosis of bronchiectasis or limits from insurers, revenue can stay below the peak that Insmed expects.
Insmed expects more than $6 billion of peak revenue from TPIP, which is still in Phase 3 studies. Studies can fail: in April 2026, brensocatib did not work in the CEDAR study in hidradenitis suppurativa.
Insmed had a net loss of $277.1 million in the first nine months of 2026, with research and development expenses of $689.5 million. If it does not become cash flow positive in 2027, it can need new capital, and options and share units for about 17.9 million shares were outstanding at September 30, 2026.
Term loans of $546.8 million, including capitalized interest, are due in 2028 and 2029, and Insmed also pays royalties under a royalty financing agreement.
The FDA can delay or refuse the ARIKAYCE label expansion, which has a target date of January 28, 2027.
- Balance sheet
- Cash: $1.1B
Debt: $547M
Net cash: $600M
Last debt due: 2029
At September 30, 2026, Insmed had cash, cash equivalents and marketable securities of $1,146.6 million, down from $1,430.0 million at December 31, 2025. Its debt is secured term loans from funds that Pharmakon manages, with principal and capitalized interest of $546.8 million: $341.7 million is due in 2028 and $205.0 million in 2029. It also has a royalty financing liability of $156.5 million and contingent consideration of $178.1 million for past acquisitions. Insmed had a net loss of $277.1 million in the first nine months of 2026, and it expects to become cash flow positive in 2027. Shareholders' equity was $726.2 million.
As of Sep 30, 2026.
- Checkpoints
- Jan 28, 2027: FDA decision on the ARIKAYCE label expansion. Pending. Watch: The FDA approves ARIKAYCE for MAC lung disease as part of a combination regimen by the target date, and this passes; a delay or a refusal fails.
Jan 29, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: BRINSUPRI revenue for 2026 is $1.35 billion or more and the 2027 guidance shows further growth, and this passes; a miss of the 2026 guidance fails.
2027 (estimate): Positive cash flow in 2027. Pending. Watch: Insmed reaches positive cash flow in 2027, as it expects, and this passes; a need for new capital to fund losses fails.
- Recent events
- Oct 29, 2026: Insmed reported third quarter 2026 results. Revenue was $524.4 million: $400.1 million from BRINSUPRI, up 29% from the second quarter, and $124.4 million from ARIKAYCE, up 9% from a year earlier. The net loss was $100.3 million. Insmed raised its 2026 revenue guidance to $1.35 billion to $1.4 billion for BRINSUPRI and $460 million to $470 million for ARIKAYCE. The FDA accepted the ARIKAYCE label expansion for priority review, with a target date of January 28, 2027.
Oct 20, 2026: Insmed added Paul Hudson, a former chief executive officer of Sanofi, and Utpal Koppikar, chief financial officer of Verily Health, to its board.
Oct 5, 2026: Insmed said that its chief financial officer, Sara Bonstein, would step down on October 30, 2026, and it started a search for a successor. It said that it expects to become cash flow positive in 2027.
Aug 6, 2026: Insmed reported second quarter 2026 results, with BRINSUPRI revenue of $309.2 million. It raised its 2026 BRINSUPRI guidance to $1.25 billion to $1.40 billion and its peak revenue estimates to more than $7 billion for BRINSUPRI, more than $6 billion for TPIP and more than $1 billion for ARIKAYCE. In August 2026, Japan approved BRINSUPRI.
Apr 7, 2026: The Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa did not meet its primary or secondary endpoints, and Insmed stopped this program.
Mar 23, 2026: The Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease met its primary endpoint and all multiplicity-controlled secondary culture conversion endpoints.
Feb 19, 2026: Insmed reported 2025 results. Revenue was $606.4 million: $172.7 million from BRINSUPRI and $433.8 million from ARIKAYCE. It expected 2026 BRINSUPRI revenue of at least $1 billion and had about $1.4 billion of cash, cash equivalents and marketable securities at the end of 2025.